91 related articles for article (PubMed ID: 2159769)
1. Tumour cell activity markers in epithelial ovarian cancer: are biochemical and cytometric indices complementary?
Redman CW; Finn C; Ward K; Kelly K; Buxton EJ; Varma R; Shortland-Webb W; Luesley DM
Br J Cancer; 1990 May; 61(5):755-8. PubMed ID: 2159769
[TBL] [Abstract][Full Text] [Related]
2. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer.
Friedlander ML; Hedley DW; Swanson C; Russell P
J Clin Oncol; 1988 Feb; 6(2):282-90. PubMed ID: 3276825
[TBL] [Abstract][Full Text] [Related]
3. Random urinary cyclic 3',5' guanosine monophosphate in epithelial ovarian cancer: relation to other prognostic variables and to survival.
Luesley DM; Blackledge GR; Chan KK; Newton JR
Br J Obstet Gynaecol; 1986 Apr; 93(4):380-5. PubMed ID: 3008807
[TBL] [Abstract][Full Text] [Related]
4. Monitoring ovarian cancer using urine cyclic GMP. A two-centre study.
Turner GA; Greggi S; Guthrie D; Benedetti Panici P; Ellis RD; Scambia G; Mancuso S
Eur J Gynaecol Oncol; 1990; 11(6):421-7. PubMed ID: 1964900
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of DNA content in epithelial ovarian cancer.
Gajewski WH; Fuller AF; Pastel-Ley C; Flotte TJ; Bell DA
Gynecol Oncol; 1994 Apr; 53(1):5-12. PubMed ID: 8175021
[TBL] [Abstract][Full Text] [Related]
6. Effect of cellular DNA content on the prognosis of epithelial ovarian cancers.
Ozalp S; Yalcin OT; Gulbas Z; Tanir HM; Minsin T
Gynecol Obstet Invest; 2001; 52(2):93-7. PubMed ID: 11586035
[TBL] [Abstract][Full Text] [Related]
7. A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate.
Ahlgren G; Lindholm K; Falkmer U; Abrahamsson PA
Urology; 1997 Sep; 50(3):379-84. PubMed ID: 9301701
[TBL] [Abstract][Full Text] [Related]
8. Value of quantitative pathological variables as prognostic factors in advanced ovarian carcinoma.
Brinkhuis M; Baak JP; Meijer GA; van Diest PJ; Mogensen O; Bichel P; Neijt JP
J Clin Pathol; 1996 Feb; 49(2):142-8. PubMed ID: 8655681
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of morphometric and DNA flow cytometric variables as independent predictors of survival in epithelial ovarian carcinoma: a 5-year follow-up study.
Veerman MM; van der Wurff AA; van de Water M; Kruitwagen RF; Feijen HW; Vos MC
Int J Gynecol Pathol; 2009 Sep; 28(5):432-41. PubMed ID: 19696612
[TBL] [Abstract][Full Text] [Related]
10. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
[TBL] [Abstract][Full Text] [Related]
11. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells.
Kimmig R; Wimberger P; Hillemanns P; Kapsner T; Caspari C; Hepp H
Gynecol Oncol; 2002 Jan; 84(1):21-31. PubMed ID: 11748971
[TBL] [Abstract][Full Text] [Related]
12. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.
Pinto AE; André S; Soares J
J Clin Pathol; 1999 Aug; 52(8):604-11. PubMed ID: 10645231
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic variables, operative characteristics, and DNA ploidy in predicting outcome in ovarian epithelial carcinoma.
Rice LW; Mark SD; Berkowitz RS; Goff BA; Lage JM
Obstet Gynecol; 1995 Sep; 86(3):379-85. PubMed ID: 7651646
[TBL] [Abstract][Full Text] [Related]
14. Influence of cellular DNA content on survival in ovarian carcinoma.
Klemi PJ; Joensuu H; Mäenpää J; Kiilholma P
Obstet Gynecol; 1989 Aug; 74(2):200-4. PubMed ID: 2748056
[TBL] [Abstract][Full Text] [Related]
15. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric analysis of DNA content in human ovarian cancers.
Erba E; Ubezio P; Pepe S; Vaghi M; Marsoni S; Torri W; Mangioni C; Landoni F; D'Incalci M
Br J Cancer; 1989 Jul; 60(1):45-50. PubMed ID: 2803914
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
[TBL] [Abstract][Full Text] [Related]
18. [Significance of PCNA proliferating fraction for prognosis of ovarian carcinoma].
Schönborn I; Minguillon C; Reles A; Bartel U; Lichtenegger W
Geburtshilfe Frauenheilkd; 1996 Jul; 56(7):357-64. PubMed ID: 8964450
[TBL] [Abstract][Full Text] [Related]
19. Nuclear β-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer.
Nagy B; Tóth L; Molnár P; Méhes G; Thurzó L; Póka R; Hernádi Z
Pathol Res Pract; 2017 Aug; 213(8):915-921. PubMed ID: 28651933
[TBL] [Abstract][Full Text] [Related]
20. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
Meyer JS; Gersell DJ; Yim S
Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
